| NCT ID | NCT03439462 |
| Title | ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Aadi, LLC |
| Indications | |
| Therapies |
Bevacizumab + Fluorouracil + Leucovorin + Nab-Rapamycin + Oxaliplatin |
| Age Groups: | senior adult |